Introduction {#tca13194-sec-0001}
============

Immune‐checkpoint inhibitors (ICIs) are widely used for the treatment of advanced non‐small cell lung cancer (NSCLC) in clinical practice.[1](#tca13194-bib-0001){ref-type="ref"}, [2](#tca13194-bib-0002){ref-type="ref"}, [3](#tca13194-bib-0003){ref-type="ref"}, [4](#tca13194-bib-0004){ref-type="ref"} Pembrolizumab, anti‐programmed death 1 (PD‐1) antibody, significantly improved a progression‐free survival and an overall survival compared with platinum‐based chemotherapy in patients who had previously untreated advanced NSCLC with programmed death ligand 1 (PD‐L1) expression on at least 50% of tumor cells and with no sensitizing epidermal growth factor receptor mutations and anaplastic lymphoma kinase translocations.[3](#tca13194-bib-0003){ref-type="ref"}, [5](#tca13194-bib-0005){ref-type="ref"} In addition, durvalumab, anti‐PD‐L1 antibody, significantly prolonged a progression‐free survival and an overall survival compared with placebo in patients with stage III, unresectable NSCLC who did not have disease progression after concurrent chemoradiotherapy.[6](#tca13194-bib-0006){ref-type="ref"} Recently, some groups have investigated the efficacy of neoadjuvant treatment with anti‐PD‐1/PD‐L1 antibodies prior to curative lung surgery in patients with resectable NSCLC.[7](#tca13194-bib-0007){ref-type="ref"} This neoadjuvant immunotherapy may be promising but the safety of treatment with ICIs prior to thoracic surgery has not been fully elucidated. Here, we report the case of a female patient with NSCLC who experienced interstitial lung disease (ILD) associated with pemblolizumab treatment after thoracic surgery.

Case report {#tca13194-sec-0002}
===========

A 62‐year‐old female with a history of smoking 32 packs per year was referred to our hospital because of an abnormal chest X‐ray. Computed tomography (CT) scan showed a mass lesion in the right middle lobe and a subpleural small nodule in the right lower lobe (Fig [1](#tca13194-fig-0001){ref-type="fig"}a). She was diagnosed with clinical stage IIIA (cT4N0M0) lung squamous cell carcinoma harboring 85% tumor proportion score of PD‐L1 (Fig [2](#tca13194-fig-0002){ref-type="fig"}a), and treated with pembrolizumab (200 mg) for three weeks. After 12 cycles of pembrolizumab, positron emission tomography/CT scan showed a radiologic partial response and a metabolic complete response in the primary tumor, although the subpleural small nodule had not changed in size (Fig [1](#tca13194-fig-0001){ref-type="fig"}b). The nodule was diagnosed as an old inflammatory change and the initial clinical stage was amended to stage IB (cT2aN0M0). A right middle partial resection was subsequently performed two months following the last administration of pembrolizumab. The pathological findings of the resection showed more than 90% regression of the primary tumor (Fig [2](#tca13194-fig-0002){ref-type="fig"}b). Three days after surgery, the patient began to complain of coughing and shortness of breath. On postoperative Day 8, a chest X‐ray showed new reticular opacities in the left lung lower field (Fig [3](#tca13194-fig-0003){ref-type="fig"}a). The chest CT scan 15 days postsurgery demonstrated ground‐glass opacities and consolidation with mild bronchiectasis in the bilateral lower lobes (Fig [1](#tca13194-fig-0001){ref-type="fig"}c). On examination, her body temperature was 37.5°C and oxygen saturation on room air was 90%. Fine crackles were audible in the bilateral lung fields. Clinical laboratory tests indicated a white blood cell count of 15 300/μL with 81.0% neutrophils and 11.0% lymphocytes, C‐reactive protein level 14.26 mg/dL, serum lactate dehydrogenase (LDH) 299 IU/L, Sp‐D 378 ng/mL and KL‐6 266 U/mL. The resected specimens were re‐examined which indicated thickness of interalveolar septa with lymphocytic infiltration without severe fibrosis in the lung tissue distant from the tumor (Fig [2](#tca13194-fig-0002){ref-type="fig"}c). Additionally, the specimens contained CD4 and CD8 lymphocytes influx (Fig [2](#tca13194-fig-0002){ref-type="fig"}d,e) and macrophages expressing PD‐L1 (Fig [2](#tca13194-fig-0002){ref-type="fig"}f). In conjunction with the clinical course, pembrolizumab‐induced ILD was strongly suspected, although pathological evaluation by bronchoscopy could not be performed because of her clinical state. Corticosteroid pulse therapy (intravenous methylprednisolone at a dose of 1000 mg for three days) was commenced which successfully alleviated her symptoms and improved the radiographic findings (Fig [3](#tca13194-fig-0003){ref-type="fig"}b,c). Subsequently, oral corticosteroid (prednisolone at a dose of 0.5 mg/kg) was initiated and tapered over five months. Based on the results of the imaging findings, the ILD was considered to have resolved (Figs [1](#tca13194-fig-0001){ref-type="fig"}d and [3](#tca13194-fig-0003){ref-type="fig"}d). Recurrence of the ILD and lung cancer have not been observed for over one year since the discontinuation of steroid therapy.

![(**a**) Computed tomography (CT) scan of the chest showed a mass lesion in the right middle lobe and a subpleural small nodule in the right lower lobe at diagnosis. (**b**) Positron emission tomography showed a radiologic partial response and a metabolic complete response in the primary tumor after 12 cycles of pembrolizumab. (**c**) CT scan 15 days operatively demonstrated extensive bilateral ground‐glass opacities and consolidation. (**d**) The interstitial lung infiltrates resolved after steroid therapy.](TCA-10-2179-g001){#tca13194-fig-0001}

![(**a, b**) Tumor tissue specimens (hematoxylin and eosin; original magnification ×200). (**a**) Before the administration of pembrolizumab and (**b**) after administration. (**c**) Normal tissues distant from the tumor showed the thickness of interalveolar septa with lymphocytic infiltration in the specimens from resected lung (hematoxylin and eosin; original magnification ×200). (**d--f**) Immunohistochemistry showed the specimens (**d**) contained CD4 lymphocytes, (**e**) CD8 lymphocytes and (**f**) macrophages expressing PD‐L1. Brown color indicates CD4, CD8 and PD‐L1.](TCA-10-2179-g002){#tca13194-fig-0002}

![(**a**) Chest X‐ray revealed new reticular opacities in the left lower lung field, as well as postsurgical pleural effusion and infiltrates in the right lung field eight days after right middle partial resection. (**b**) The reticular opacities in the left lower lung field worsened 15 days postoperatively. (**c**) Following steroid pulse therapy, the opacities had slightly reduced. (**d**) All findings improved after oral corticosteroid therapy over five months.](TCA-10-2179-g003){#tca13194-fig-0003}

Discussion {#tca13194-sec-0003}
==========

To our knowledge, this is the first case report of pembrolizumab‐induced ILD triggered by thoracic surgery. In this case, infiltration of T lymphocytes and abundant macrophages expressing PD‐L1 were observed in normal tissues in the post‐immunotherapy specimens, which is consistent with previous reports.[7](#tca13194-bib-0007){ref-type="ref"}, [8](#tca13194-bib-0008){ref-type="ref"} We assumed that the PD‐1 blockade reactivated T‐cell effector function resulting in focal inflammatory changes in lung parenchyma (pathological ILD) prior to the thoracic surgery.

Thoracic surgery has been known to be a risk factor for acute respiratory distress syndrome (ARDS) and acute exacerbation of ILD is a major cause of postsurgical ARDS.[9](#tca13194-bib-0009){ref-type="ref"} Although the precise mechanisms of postoperative acute exacerbation of ILD have not yet been elucidated, it may be associated with a release of inflammatory cytokines and reactive oxygen species from immune cells. Previous reports demonstrated that levels of IL‐6 and oxidative stress were elevated in patients with acute exacerbation of idiopathic pulmonary fibrosis (IPF) compared with those with stable IPF.[10](#tca13194-bib-0010){ref-type="ref"}, [11](#tca13194-bib-0011){ref-type="ref"} The pathogenesis of ILD in this case may not be the same as that of postoperative acute exacerbation of IPF because steroid therapy in this case was more effective than that for postoperative acute exacerbation of IPF. ICIs‐related ILD is mostly low grade event and improves with drug discontinuation and immunosuppression.[12](#tca13194-bib-0012){ref-type="ref"} In this case, we speculated the pembrolizumab‐induced pathological ILD deteriorated into radiological ILD due to an enhancement of T‐cell effector function by surgical stress.[13](#tca13194-bib-0013){ref-type="ref"} Thoracic surgery following immunotherapy may have a risk of developing immunotherapy‐related ILD, and careful monitoring is required for early detection of ILD after surgery.
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